2019
DOI: 10.1080/17474086.2019.1615878
|View full text |Cite
|
Sign up to set email alerts
|

Current treatment of lymphoma in pregnancy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
22
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
2

Relationship

0
8

Authors

Journals

citations
Cited by 11 publications
(23 citation statements)
references
References 114 publications
1
22
0
Order By: Relevance
“…There were no significant differences in spontaneous abortion and preterm delivery, whereas adverse events in the neonates were similar in both groups [8]. Similar conclusions were drawn from studies on pregnant women with breast cancer or lymphoma and other malignancies [9][10][11]. In an attempt to validate the beneficial role of GCSF for the treatment of unexplained recurrent miscarriage proposed by a previous study, a randomized, double-blind, placebo controlled clinical trial involving 150 women with a history of unexplained recurrent pregnancy loss was conducted.…”
Section: Granulocyte Colony-stimulating Factorsupporting
confidence: 73%
“…There were no significant differences in spontaneous abortion and preterm delivery, whereas adverse events in the neonates were similar in both groups [8]. Similar conclusions were drawn from studies on pregnant women with breast cancer or lymphoma and other malignancies [9][10][11]. In an attempt to validate the beneficial role of GCSF for the treatment of unexplained recurrent miscarriage proposed by a previous study, a randomized, double-blind, placebo controlled clinical trial involving 150 women with a history of unexplained recurrent pregnancy loss was conducted.…”
Section: Granulocyte Colony-stimulating Factorsupporting
confidence: 73%
“…All included studies were case reports and original articles. Ten studies diagnosed pregnant women with nodular sclerosis HL [ 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ], Five described management of pregnant women diagnosed with lymphocyte-rich HL [ 14 , 15 , 16 , 17 , 18 ], and one study described management of pregnant patient with stage-4 classical HL [ 19 ]. Ten of the included studies treated all pregnant patients diagnosed with HL with standard cycle of ABVD with no report of maternal or fetal complications from the chemotherapy regimen [ 5 , 6 , 7 , 8 , 9 , 10 , 12 , 17 , 19 ], but with the exception of three studies; in which one of the three studies reported that ABVD chemo therapy resulted in preterm contraction and rupture of membrane [ 5 ], second study described the addition of 25 mg/m 2 doxorubicin per cycle of ABVD which resulted in left cardiac dysfunction with high levels of troponin in the newborn on day 4 of life which later resolved on month one of life [ 16 ], and the third study reported an adverse effect with ABVD chemotherapy resulting in preterm birth, and the need for immediate post-partum blood transfusion with subsequent development of venous thromboembolism in the mother [ 11 ].…”
Section: Resultsmentioning
confidence: 99%
“…For the treatment of HL with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone), five studies [ 4 , 9 , 12 , 14 , 15 ] reported no complication with the chemo regimen in pregnant patients and their fetuses. It was observed that R-CHOP was commonly used for the chemotherapeutic regimen in pregnant patients diagnosed with lymphocyte-rich HL while ABVD regimen was more popular for the treatment of nodular sclerosing HL.…”
Section: Resultsmentioning
confidence: 99%
“…In regards to the safety of G-CSF on the developing embryo, several studies have looked into the effects of G-CSF in pregnant patients with cancer and found no significant difference in teratogenicity between patients prescribed G-CSF and individuals not prescribed G-CSF, thereby indicating that G-CSF had no teratogenic effect on the developing fetus (Zeidler et al, 2014;Boxer et al, 2015;Gurevich-Shapiro & Avivi, 2019;Cardonick et al, 2012).…”
Section: Discussionmentioning
confidence: 99%